Company Long-Term Loans and Borrowings: Voyager Pharma (VYGR)

Graphic logo of Voyager Corp (VYGR)

The market capitalization trend for Voyager Therapeutics (VYGR) reflects the dynamics of a company developing CNS gene therapy methods based on unique platforms, where the key metric equals 0.03. The business leverages AI algorithms and automation to accelerate capsid selection, minimizing manual labor. Process stability is maintained through specialized biotech hubs and streamlined raw material supply chains for laboratories.

voyagertherapeutics.com (VYGR) Company Long-Term Liabilities: for the period 07/04/2022 - 11/01/2026

Voyager Pharma - analytical breakdowns and key metrics (VYGR)

- market price and analyst price targets:
Stock Price voyagertherapeutics.com|VYGR - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Voyager Therapeutics|VYGR - Total Company Value
- book capitalization information:
Net Asset Value per Share Voyager Therapeutics|VYGR - Company Net Assets|Market Value to Book Value Ratio voyagertherapeutics.com|VYGR - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Capital Voyager Therapeutics|VYGR - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Voyager Corp|VYGR - Company Aggregate Debts|Debts to Book Capitalization Voyager Therapeutics|VYGR - Company Long-Term Debts|Short-Term Indebtedness Voyager Therapeutics|Immediate Liquidity voyagertherapeutics.com
- earnings and market multiples details:
VYGR - Company Net Income
Summary company analytics:VYGR (voyagertherapeutics.com)
Manufactured product of Voyager Therapeutics, Inc.

This indicator measures total liabilities with maturities exceeding one year, allowing for an assessment of long-term financial stability and the risk of balance sheet overload. By analyzing the company's long-term debt value, an investor can identify the resource base available for scaling R&D projects. For Voyager Therapeutics (VYGR), such borrowings are balanced by revenues from licensing agreements with pharma behemoths. An optimal ratio of loans to partner payments confirms the company's ability to develop neuropharmaceutical platforms without the threat of default.

Who Voyager Therapeutics competes with

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|Company Long-Term Liabilities XENE|Company Long-Term Debt VKTX|Company Long-Term Debt Supernus (SUPN)|CPRX - Long-Term Debt|Denali Therapeutics Inc - Company Long-Term Liabilities|Harmony Corp (HRMY) - Long-Term Debt|Biohaven Ltd. - Company Long-Term Debts|AMLX - Company Long-Term Debts|TRVI: Company Long-Term Debts|Long-Term Indebtedness Praxis Precision Medicines Inc PRAX|AVXL (Anavex Corp) - Company Long-Term Debts|Long-Term Debt CeriBell EEG CBLL|Company Long-Term Debt Prothena (PRTA)|ALEC (alector.com) - Company Long-Term Loans and Borrowings|Annexon - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings OMER|NGNE: Company Long-Term Liabilities|AC Immune Inc - Amount of Long-Term Liabilities|NMRA: Company Long-Term Debts|scilexholding.com - Company Long-Term Loans and Borrowings|TVGN (Tevogen Bio) - Company Long-Term Debts|Long-Term Debt Alpha Cognition Corp ACOG|Company Long-Term Debt Cognition Therapeutics (CGTX)|IKT (Inhibikase Pharma) - Company Long-Term Loans and Borrowings|Company Long-Term Debts SAVA (Cassava Sciences, Inc.)|Company Long-Term Debts Assertio Holdings ASRT|COYA - Company Long-Term Debt|Long-Term Liabilities VTGN|OVID: Company Long-Term Debts|Long-Term Debt Acumen Pharmaceuticals, Inc (ABOS)|Company Long-Term Liabilities CRVO|Company Long-Term Debts Alterity Therapeutics Ltd|Company Long-Term Liabilities CLNN (Clene Inc.)|Amount of Long-Term Liabilities PEPG|Company Long-Term Debts JUNS (Jupiter Neurosciences Inc)|Long-Term Debt Volume Relmada Corp (RLMD)|Annovis Bio, Inc. - Company Long-Term Debts|Grace Therapeutics, Inc. (GRCE) - Company Long-Term Liabilities|Firefly Neuroscience (AIFF) - Company Long-Term Debt|KLTO - Long-Term Debt Volume|Company Long-Term Liabilities NRSN|Company Long-Term Debt RVPH|Company Long-Term Liabilities MTVA (MetaVia Inc)|NRXS - Long-Term Debt|Company Long-Term Debts HSDT (Helius Medical Technologies)|Long-Term Indebtedness Passage Bio Inc.|NEUP - Company Long-Term Debt|Company Long-Term Loans and Borrowings NERV (Minerva)|Athira Pharma, Inc. (ATHA) - Company Long-Term Debt|Company Long-Term Indebtedness ADXN|ALZN (Alzamend Neuro Inc.) - Company Long-Term Debts|Long-Term Debt Cyclerion CYCN|Company Long-Term Liabilities PTIX (Protagenic Therapeutics)|Company Long-Term Debts pasitheaclinics.com (KTTA)|Company Long-Term Debt Cortigent CRGT|Company Long-Term Loans and Borrowings ATXI|BCLI - Company Long-Term Debt|Long-Term Debt Cara Therapeutics Inc.|CHRO (Chromocell Therapeutics Corporation) - Company Long-Term Liabilities|ELYM (Eliem Therapeutics Inc.) - Company Long-Term Debt|Company Long-Term Debt Intra-Cellular Therapies Inc.|Long-Term Debt longboardpharma.com LBPH|Company Long-Term Liabilities MRNS (Marinus Pharmaceuticals, Inc.)|NKGN - Long-Term Debt|Company Long-Term Debts NRBO (NeuroBo)|Company Long-Term Debts Sage Therapeutics Inc SAGE|Synaptogenix, Inc. - Company Long-Term Debts|Long-Term Indebtedness trevena.com (TRVN)|VIGL: Company Long-Term Debts|Long-Term Debt Anew Medical Inc. (WENA)|Company Long-Term Debt Cerevel